RB and cell cycle progression

@article{Giacinti2006RBAC,
  title={RB and cell cycle progression},
  author={Cristina Giacinti and Antonio Giordano},
  journal={Oncogene},
  year={2006},
  volume={25},
  pages={5220-5227}
}
The Rb protein is a tumor suppressor, which plays a pivotal role in the negative control of the cell cycle and in tumor progression. It has been shown that Rb protein (pRb) is responsible for a major G1 checkpoint, blocking S-phase entry and cell growth. The retinoblastoma family includes three members, Rb/p105, p107 and Rb2/p130, collectively referred to as ‘pocket proteins’. The pRb protein represses gene transcription, required for transition from G1 to S phase, by directly binding to the… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 373 CITATIONS, ESTIMATED 44% COVERAGE

Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization

  • Cell Death and Disease
  • 2015
VIEW 11 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Checkpoint controls and targets in cancer therapy

VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Causes and consequences of nuclear envelope alterations in tumour progression.

  • European journal of cell biology
  • 2016
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Roles of pRB in the Regulation of Nucleosome and Chromatin Structures

  • BioMed research international
  • 2016
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1992
2019

CITATION STATISTICS

  • 16 Highly Influenced Citations

  • Averaged 29 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Cancer Res 56: 2003–2008

  • Claudio PP, Tonin T, Giordano A. (2002). Genome 3: 3012. Claudio PP, Howard CM, Fu Y. (2000). Cancer Res 60:
  • 1996
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Oncogene 44: 30–33

DK Dimova, N. Dyson
  • J Cell Sci
  • 2005
VIEW 1 EXCERPT

Oncogene 49: 7337–7345

Abbady
  • Jackman M, Firth M, Pines J. (1995). EMBO J 14: 1646–1654. Johnson DG, Schendeider-Broussard R. (1998). Front Biosci 3:
  • 2005

Yonsei Med J 31: 597–613

YT Kim, M. Zhao
  • Knudson AG. (1971). Proc Natl Acad Sci USA 68: 820–823. Lai A, Lee JM, Yang WM, De Caprio JA, Keelin WG et al.
  • 2005

Cancer Cell 5: 539–551

R. Bremner
  • Cinti C, Giordano A. (2000). Emerg Ther Targets 4: 765–783. Cinti C, Leoncini L, Nwongo A. (2000). Am J Pathol 156:
  • 2004

EMBO J 23: 4627–4638

S. Gaubatz
  • Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR,
  • 2004

Cancer Cell 2: 463–472

BD.
  • Lee JO, Russo AA, Pavletich NP. (1998). Nature 391: 859–865. Lee MH, Williams Bo, Mulligan G. (1996). Genes Dev 16:
  • 2002

Gene 251: 37–43

K. Shimizu
  • Jeanblanc M, Mousli M, Hopfner R, Bathami K, Martinet N,
  • 2000

Mol Cell 6: 729–735

DM Livingston
  • Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HI et al.
  • 2000

Nature 406: 593–599

S Schmid Ren
  • Ren S, Rollins BJ. (2004). Dev Cell 6: 607–608. Resnitzky D, Gossen M, Buiard H, Reed SI. (1994). Mol Cell
  • 2000